Bisphosphonates Side Effects: Oral, IV, and Long-Term Risks

Bisphosphonates are the most widely prescribed drugs for osteoporosis, and their side-effect profile runs from everyday nuisances like heartburn all the way to rare but serious complications including jawbone damage and unusual thigh fractures. Most people tolerate these medications well, but the range of possible effects is broader than many patients realize, and some risks shift depending on how the drug is taken, how long therapy continues, and what other health conditions are in play.

How Bisphosphonates Create Side Effects in the First Place

Bisphosphonates work by binding tightly to bone mineral and then hitching a ride into osteoclasts, the cells responsible for breaking down old bone. The newer, nitrogen-containing versions (alendronate, risedronate, ibandronate, and zoledronate) block an enzyme called farnesyl pyrophosphate synthase inside those cells, which essentially paralyzes and eventually kills them.¹ Older, non-nitrogen bisphosphonates work differently: they get converted into toxic molecules that build up inside the osteoclast and trigger cell death.² This core mechanism, shutting down the cells that remodel bone, explains both the benefit (less bone loss) and several of the long-term risks (bone that cannot repair itself properly). The short-term side effects, like stomach irritation and flu-like reactions, come from a different set of mechanisms tied to how the drug contacts tissue or triggers the immune system.

Gastrointestinal Problems With Oral Bisphosphonates

Stomach and esophageal irritation are the complaints that drive the most people to stop oral bisphosphonates. The pills are chemically harsh on mucosal tissue. Early reports on alendronate documented erosions and ulcerations in the esophagus, often with visible inflammation and thickening of the esophageal wall on endoscopy.³ This is why the dosing instructions feel oddly specific: take the pill first thing in the morning, with a full glass of plain water, stay upright for at least half an hour, and do not eat or drink anything else during that window. Those instructions are not just suggestions. They exist to keep the tablet from lingering in the esophagus or stomach longer than necessary.

When the tablet does linger, the consequences can be worse than heartburn. A case report documented oral ulceration of the tongue and lower lip in a patient with advanced dementia whose caregivers did not realize the tablet had not been fully swallowed. The authors noted that dysphagia and physical impairment are leading causes of oral bisphosphonate-associated ulceration.⁴ For anyone who has trouble swallowing pills or who cannot sit upright reliably, an intravenous bisphosphonate may be a better fit simply because the drug never touches the upper digestive tract.

Flu-Like Symptoms After IV Infusions

Intravenous zoledronate sidesteps the gut entirely, but it comes with its own acute reaction. Within a day or two of the first infusion, many patients develop fever, muscle and joint aches, and a general feeling that resembles the flu. A study of women receiving zoledronate for osteoporosis found that these symptoms were the main adverse effects, described as mild, and they resolved with basic over-the-counter treatment.⁵ The reaction tends to be strongest with the first infusion and milder or absent with subsequent doses. Taking acetaminophen or ibuprofen before and after the infusion is a common strategy, and many clinics recommend it routinely.

Osteonecrosis of the Jaw

This is the side effect that gets the most attention, partly because it sounds alarming and partly because dental professionals routinely screen for it. Bisphosphonate-related osteonecrosis of the jaw (sometimes abbreviated BRONJ or MRONJ, for medication-related osteonecrosis) involves exposed bone in the mouth that fails to heal. The principal risk factors are tooth extractions, other surgical procedures in the mouth, and high doses of bisphosphonates, particularly the intravenous regimens used in cancer treatment.⁶

The mechanism appears to hinge on the bone being exposed to bacteria in the mouth. One review concluded that necrotic lesions seem to follow upon exposure of bone (for example, after a tooth extraction), while procedures like implant placement do not appear to raise the risk in the same way. The authors argued the condition is essentially a form of chronic bone infection and should be treated as such.⁷ For people taking standard osteoporosis doses of oral bisphosphonates, the risk is quite low. The higher-risk population is cancer patients receiving high-dose intravenous bisphosphonates, where the cumulative drug exposure is much greater.

Despite widespread concern, there is still no proven prevention protocol for patients who need dental extractions. A systematic review found no conclusive scientific evidence on the efficacy of jaw osteonecrosis prevention protocols in patients on bisphosphonates who undergo tooth extraction.⁸ Some surgical teams have developed standardized approaches combining antibiotics, careful surgical technique, and antiseptic rinses. One study of high-risk cancer patients using such a protocol reported that about 13% still developed jaw osteonecrosis after extractions, and the risk was especially elevated when bone had to be cut during the procedure, particularly in the lower jaw.⁹ The practical takeaway for most osteoporosis patients: let your dentist know you take a bisphosphonate, but do not skip necessary dental work out of fear. The risk at osteoporosis doses is small, and untreated dental infections carry their own dangers.

Atypical Femoral Fractures

This is perhaps the most paradoxical side effect of a drug meant to prevent fractures. Atypical femoral fractures are unusual breaks that occur in the shaft of the thighbone, often with little or no trauma, sometimes preceded by weeks of dull thigh pain. They look different from ordinary osteoporotic hip fractures and tend to occur in a specific location along the bone.

The risk rises with longer bisphosphonate use. A large study found that compared with people who used bisphosphonates for less than three months, the risk of atypical fracture roughly nine-fold higher at three to five years and over forty-fold higher at eight years or more.¹⁰ Those relative numbers sound dramatic, but they need context: the absolute risk remains low because atypical fractures are rare events to begin with. The same researchers weighed the risk of atypical fracture against the fractures prevented by bisphosphonate therapy, and the balance still favored treatment for most patients over the first several years.

There also appears to be a genetic component. A case report described a mother and daughter who both developed bilateral atypical femoral fractures after relatively short courses of bisphosphonate therapy, raising the possibility that some families may be predisposed.¹¹ If a close family member has experienced this complication, it is worth mentioning to your doctor.

The Microcrack Paradox

Healthy bone constantly tears itself down and rebuilds. This remodeling process patches microcracks that accumulate from everyday stress. Bisphosphonates slow that remodeling dramatically, which is the point: less breakdown means denser bone. But there is a tradeoff. An animal study found that one year of bisphosphonate treatment suppressed bone remodeling by over half and significantly increased microdamage accumulation, with one drug raising microcrack density more than threefold. Bone toughness, the ability to absorb energy before breaking, dropped by about a fifth with the higher dose.¹²

Human data tells a similar story. A study comparing bone tissue from bisphosphonate-treated fracture patients, untreated fracture patients, and healthy aging individuals found that bisphosphonate-treated bone had the highest density of microcracks. Those samples also showed reduced tensile strength. The authors noted that while bisphosphonates do protect against the development of larger perforations in bone by limiting osteoclast activity, the oversuppression of remodeling allows microcracks to accumulate and propagate, potentially weakening the bone in a different way.¹³ This microcrack accumulation is thought to be part of the mechanism behind atypical femoral fractures.

Kidney Safety

All bisphosphonates carry labeled warnings against use in patients with severely impaired kidney function, generally defined as a creatinine clearance below 30 to 35 mL/min.¹⁴ The concern is especially relevant for intravenous zoledronate. An analysis of adverse event reports found that among kidney-related side effects associated with zoledronate, damage to the kidney tubules was the most frequently reported problem in patients with breast cancer and osteoporosis.¹⁵ Laboratory work has shown that zoledronate at concentrations similar to clinical doses can trigger oxidative stress and cell death in kidney cells.¹⁶

In practice, kidney function is checked before starting treatment. A study in older adults with impaired kidney function found that long-term kidney function trajectories stayed stable on bisphosphonate therapy, but the risk of acute adverse events was elevated in patients with a creatinine clearance below 35 mL/min, reinforcing the need for monitoring in that group.¹⁷ For people with significant kidney disease, the alternative drug denosumab may be preferred, since it does not depend on kidney clearance.¹⁸

Hypocalcemia and the Importance of Vitamin D

Because bisphosphonates slow bone breakdown, they also reduce the release of calcium from bone into the bloodstream. In most people, the body compensates easily. But in patients who already have low vitamin D levels, impaired kidney function, or underactive parathyroid glands, bisphosphonates can push blood calcium dangerously low.¹⁹ Symptoms of severe hypocalcemia include muscle spasms, tingling in the hands and face, and in extreme cases, seizures or heart rhythm disturbances. This is why guidelines call for checking vitamin D status and kidney function before starting therapy, and why calcium and vitamin D supplementation during treatment is considered mandatory.²⁰

Atrial Fibrillation

A possible link between bisphosphonates and the heart rhythm disorder atrial fibrillation was first flagged in a major zoledronate trial and has been investigated repeatedly since. A meta-analysis of observational studies found that bisphosphonate users had a modestly elevated risk of atrial fibrillation, with an odds ratio around 1.17, though there was substantial variability across the studies pooled.²¹ A separate meta-analysis that included randomized trials found a slightly higher pooled risk in observational data and a statistically significant increase in serious atrial fibrillation in the trial data, but no increase in stroke or cardiovascular death.²² A pharmacovigilance study looking at international adverse-event databases found that cardiac events (excluding heart attacks) appeared more common with bisphosphonates than with the bone-building drug teriparatide.²³

The absolute increase in risk, if real, appears small, and the mechanism is not well understood. For most patients, this signal is not a reason to avoid bisphosphonates. But if you already have atrial fibrillation or strong risk factors for it, it is worth discussing with your prescriber.

Eye Inflammation

This one surprises most patients and even some doctors. Bisphosphonates have been linked to inflammatory eye reactions including uveitis, scleritis, and conjunctivitis.²⁴ These reactions are rare but are well documented in case reports, and some cases recurred when patients were re-exposed to the same or another bisphosphonate, suggesting a genuine drug effect. Interestingly, large population-based studies have shown conflicting results, and some researchers have argued that the eye inflammation may actually be part of an underlying inflammatory disease process that also causes osteoporosis, rather than a direct drug effect.²⁵ Either way, if you develop a red, painful eye or vision changes while on a bisphosphonate, see an ophthalmologist promptly and mention the medication.

Drug Holidays and the Question of How Long to Treat

Because bisphosphonates embed themselves in bone and continue to act for years after you stop taking them, doctors can offer something unusual for a chronic disease medication: a planned break from treatment, commonly called a drug holiday. The rationale is that continued suppression of bone remodeling increases the risk of atypical fractures and microcrack accumulation, so a pause may let the skeleton recover some of its repair capacity while still benefiting from residual drug in the bone.²⁶

A population-based cohort study of women who took a bisphosphonate holiday of at least twelve months after three or more years of use found no increase in overall osteoporosis-related fracture risk or hip fracture risk compared to women who continued treatment without a break. There was actually a slight reduction in vertebral fracture risk in the holiday group.²⁷ That said, the optimal timing, both when to start a holiday and how long it should last, remains a judgment call based on individual fracture risk. Patients at very high risk of spine or hip fractures may not be good candidates for a pause.

How Bisphosphonates Compare to Alternatives

When side effects become a concern, patients often ask about switching to something else. The two most common alternatives are denosumab (a biologic injection given every six months) and teriparatide (a daily injection that builds new bone rather than slowing breakdown).

Denosumab shares some of the same rare complications as bisphosphonates, including jaw osteonecrosis and atypical femoral fractures, though it avoids the gastrointestinal and kidney issues. One key difference: bisphosphonates remain embedded in bone and continue working for years after discontinuation, while denosumab’s effects reverse quickly once you stop. That rebound effect can actually increase fracture risk, so stopping denosumab without a transition plan is generally discouraged.²⁸

Teriparatide takes a completely different approach, stimulating bone formation rather than blocking resorption. Meta-analyses comparing the two classes found no significant difference in overall adverse event rates, and teriparatide actually showed a lower risk of vertebral fractures in head-to-head comparisons, though nonvertebral fracture rates were similar.²⁹ Teriparatide is generally reserved for people at high fracture risk, partly because of cost and partly because it requires daily injections for up to two years.

The Regulatory Timeline That Shaped Current Practice

The side-effect profile of bisphosphonates was not fully appreciated when these drugs first came to market. The labeling for alendronate, one of the earliest and most popular options, has been updated more than a dozen times since its approval. Gastrointestinal warnings came in 2002, jaw osteonecrosis precautions were added in 2005, musculoskeletal pain warnings in 2008, and the atypical femoral fracture warning in 2010.³⁰ That 2010 communication was a turning point: it prompted the FDA to require a formal risk evaluation strategy for the entire bisphosphonate class regarding atypical fractures, and the American Society for Bone and Mineral Research issued its own consensus recommendations.³¹ The result was a noticeable drop in bisphosphonate prescriptions, which created its own problem: many people who genuinely needed fracture prevention stopped getting it.

Bisphosphonates and Pregnancy

Because bisphosphonates persist in bone for years, women of childbearing age sometimes worry about effects on a future pregnancy even after they stop the drug. The data here is reassuring but limited. A review of pregnancy outcomes following in utero bisphosphonate exposure concluded that use before conception and during the first trimester does not appear to pose substantial fetal risks.³² The label still advises against use in pregnancy based on theoretical concerns from animal studies, but for women who took bisphosphonates before realizing they were pregnant, the existing human data is largely reassuring. The more relevant question for younger women with osteoporosis is usually whether bisphosphonates are the right choice at all, given that alternative treatments without such long skeletal half-lives exist.